Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Vilazodone Hydrochloride Tablets, 10 mg, 20 mg, and 40 mg. Please find enclosed herewith our press release. Alembic Pharmaceuticals Ltd - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the legal heir(s) of the registered shareholder(s) have requested the Company for issue of duplicate share certificate(s). ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of Notice of Board Meeting published in English and vernacular language (Gujarati) newspaper on 9th January, 2020 in Economic Times English and Gujarati Edition. Alembic Pharma rises as JV firm completes inspection
Alembic Pharma manufactures and markets generic pharmaceutical products across the globe. Alembic Pharmaceuticals Ltd - 533573 - Alembic Pharmaceuticals Limited Announces Successful Completion Of USFDA Inspection At Aleor Dermaceuticals Limited
With reference to the captioned subject, this is to inform the exchange that Aleor Dermaceuticals Ltd. (Aleor), a 60:40 Joint Venture between Alembic Pharmaceuticals Ltd. (Alembic) and Orbicular Pharmaceutical Technologies Pvt. Ltd. (Orbicular), has completed United States Food and Drug Administration (USFDA) inspection at its formulation manufacturing facility located at Karakhadi, Gujarat, India; without any observations. The inspection was carried out from 6th January, 2020 to 8th January, 2020. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The exchange is hereby informed that the Company will hold Post Results Conference Call on 22nd January, 2020 as per the enclosed details. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Board Meeting Intimation for Board Meeting To Consider Unaudited Financial Results For The Quarter And Nine Months Period Ended 31St December, 2019
ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/01/2020 ,inter alia, to consider and approve Unaudited Financial Results of the Company for the quarter and nine months period ended 31st December, 2019. Pursuant to the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives, the trading window for dealing in securities of the Company which was closed from 1st January, 2020, will re-open 48 hours after the declaration of the financial results on 22nd January, 2020. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
With reference to the captioned matter, please find enclosed herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st December, 2019, received from M/s. Link Intime India Private Limited, Registrar and Share Transfer Agent of our Company. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Shareholding for the Period Ended December 31, 2019
Alembic Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click here ALEMBIC PHARMACEUTICALS LTD. - 533573 - Statement Of Investor Complaints For The Quarter Ended December 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Charandeep Singh SalujaDesignation :- Company Secretary and Compliance Officer